Free Trial
→ Before you buy SpaceX shares, consider this alternative approach (From Weiss Ratings) (Ad)tc pixel Free MDNA Stock Alerts

Medicenna Therapeutics (MDNA) Competitors

Medicenna Therapeutics logo
C$0.44 +0.02 (+3.57%)
As of 01:18 PM Eastern
Compare

MDNA vs. APM, GXE, CGC, WMD, and EQ

Should you buy Medicenna Therapeutics stock or one of its competitors? MarketBeat compares Medicenna Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Medicenna Therapeutics include Andean Precious Metals (APM), Gear Energy (GXE), Canadian Gold (CGC), WeedMD (WMD), and EQ (EQ). These companies are all part of the "pharmaceutical products" industry.

How does Medicenna Therapeutics compare to Andean Precious Metals?

Medicenna Therapeutics (TSE:MDNA) and Andean Precious Metals (CVE:APM) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

In the previous week, Medicenna Therapeutics had 2 more articles in the media than Andean Precious Metals. MarketBeat recorded 2 mentions for Medicenna Therapeutics and 0 mentions for Andean Precious Metals. Medicenna Therapeutics' average media sentiment score of 0.00 equaled Andean Precious Metals'average media sentiment score.

Company Overall Sentiment
Medicenna Therapeutics Neutral
Andean Precious Metals Neutral

0.4% of Medicenna Therapeutics shares are owned by institutional investors. Comparatively, 13.2% of Andean Precious Metals shares are owned by institutional investors. 22.6% of Medicenna Therapeutics shares are owned by company insiders. Comparatively, 69.4% of Andean Precious Metals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Andean Precious Metals has higher revenue and earnings than Medicenna Therapeutics. Medicenna Therapeutics is trading at a lower price-to-earnings ratio than Andean Precious Metals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.15N/A
Andean Precious MetalsC$154.78M0.88C$37.41MC$0.512.55

Andean Precious Metals has a net margin of 16.17% compared to Medicenna Therapeutics' net margin of -533,640.00%. Andean Precious Metals' return on equity of 20.32% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Medicenna Therapeutics-533,640.00% -103.51% -32.80%
Andean Precious Metals 16.17%20.32%4.13%

Medicenna Therapeutics has a beta of 2.900601, meaning that its share price is 190% more volatile than the broader market. Comparatively, Andean Precious Metals has a beta of 1.22, meaning that its share price is 22% more volatile than the broader market.

Summary

Andean Precious Metals beats Medicenna Therapeutics on 9 of the 11 factors compared between the two stocks.

How does Medicenna Therapeutics compare to Gear Energy?

Gear Energy (TSE:GXE) and Medicenna Therapeutics (TSE:MDNA) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

Gear Energy has a net margin of 5.77% compared to Medicenna Therapeutics' net margin of -533,640.00%. Gear Energy's return on equity of 3.52% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Gear Energy5.77% 3.52% 4.84%
Medicenna Therapeutics -533,640.00%-103.51%-32.80%

Gear Energy has a beta of 3.52, suggesting that its stock price is 252% more volatile than the broader market. Comparatively, Medicenna Therapeutics has a beta of 2.900601, suggesting that its stock price is 190% more volatile than the broader market.

In the previous week, Medicenna Therapeutics had 2 more articles in the media than Gear Energy. MarketBeat recorded 2 mentions for Medicenna Therapeutics and 0 mentions for Gear Energy. Gear Energy's average media sentiment score of 0.00 equaled Medicenna Therapeutics'average media sentiment score.

Company Overall Sentiment
Gear Energy Neutral
Medicenna Therapeutics Neutral

Gear Energy has higher revenue and earnings than Medicenna Therapeutics. Medicenna Therapeutics is trading at a lower price-to-earnings ratio than Gear Energy, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gear EnergyC$134.93M0.00C$13.02MC$0.05N/A
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.15N/A

2.4% of Gear Energy shares are owned by institutional investors. Comparatively, 0.4% of Medicenna Therapeutics shares are owned by institutional investors. 7.6% of Gear Energy shares are owned by insiders. Comparatively, 22.6% of Medicenna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Gear Energy beats Medicenna Therapeutics on 9 of the 11 factors compared between the two stocks.

How does Medicenna Therapeutics compare to Canadian Gold?

Canadian Gold (CVE:CGC) and Medicenna Therapeutics (TSE:MDNA) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, risk, institutional ownership and earnings.

Canadian Gold has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. Canadian Gold's return on equity of -92.98% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Canadian GoldN/A -92.98% -48.06%
Medicenna Therapeutics -533,640.00%-103.51%-32.80%

0.3% of Canadian Gold shares are held by institutional investors. Comparatively, 0.4% of Medicenna Therapeutics shares are held by institutional investors. 43.3% of Canadian Gold shares are held by insiders. Comparatively, 22.6% of Medicenna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Canadian Gold is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Canadian GoldN/AN/A-C$3.62M-C$0.02N/A
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.15N/A

Canadian Gold has a beta of -1.586234, indicating that its stock price is 259% less volatile than the broader market. Comparatively, Medicenna Therapeutics has a beta of 2.900601, indicating that its stock price is 190% more volatile than the broader market.

In the previous week, Medicenna Therapeutics had 2 more articles in the media than Canadian Gold. MarketBeat recorded 2 mentions for Medicenna Therapeutics and 0 mentions for Canadian Gold. Canadian Gold's average media sentiment score of 0.00 equaled Medicenna Therapeutics'average media sentiment score.

Company Overall Sentiment
Canadian Gold Neutral
Medicenna Therapeutics Neutral

Summary

Canadian Gold and Medicenna Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Medicenna Therapeutics compare to WeedMD?

Medicenna Therapeutics (TSE:MDNA) and WeedMD (CVE:WMD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation.

WeedMD has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. WeedMD's return on equity of 0.00% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Medicenna Therapeutics-533,640.00% -103.51% -32.80%
WeedMD N/A N/A N/A

0.4% of Medicenna Therapeutics shares are held by institutional investors. 22.6% of Medicenna Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Medicenna Therapeutics has higher earnings, but lower revenue than WeedMD. Medicenna Therapeutics is trading at a lower price-to-earnings ratio than WeedMD, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.15N/A
WeedMDC$27.53M2.46-C$102.60M-C$0.42N/A

In the previous week, Medicenna Therapeutics had 2 more articles in the media than WeedMD. MarketBeat recorded 2 mentions for Medicenna Therapeutics and 0 mentions for WeedMD. Medicenna Therapeutics' average media sentiment score of 0.00 equaled WeedMD'saverage media sentiment score.

Company Overall Sentiment
Medicenna Therapeutics Neutral
WeedMD Neutral

Summary

Medicenna Therapeutics and WeedMD tied by winning 5 of the 10 factors compared between the two stocks.

How does Medicenna Therapeutics compare to EQ?

Medicenna Therapeutics (TSE:MDNA) and EQ (CVE:EQ) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, earnings, risk and institutional ownership.

In the previous week, Medicenna Therapeutics and Medicenna Therapeutics both had 2 articles in the media. EQ's average media sentiment score of 0.15 beat Medicenna Therapeutics' score of 0.00 indicating that EQ is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Medicenna Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
EQ
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Medicenna Therapeutics has a beta of 2.900601, indicating that its share price is 190% more volatile than the broader market. Comparatively, EQ has a beta of 0.112081, indicating that its share price is 89% less volatile than the broader market.

0.4% of Medicenna Therapeutics shares are held by institutional investors. Comparatively, 0.1% of EQ shares are held by institutional investors. 22.6% of Medicenna Therapeutics shares are held by company insiders. Comparatively, 12.8% of EQ shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

EQ has higher revenue and earnings than Medicenna Therapeutics. EQ is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.15N/A
EQC$10.54M6.34-C$4.66M-C$0.02N/A

EQ has a net margin of -11.73% compared to Medicenna Therapeutics' net margin of -533,640.00%. EQ's return on equity of 50.96% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Medicenna Therapeutics-533,640.00% -103.51% -32.80%
EQ -11.73%50.96%-18.43%

Summary

EQ beats Medicenna Therapeutics on 7 of the 11 factors compared between the two stocks.

Get Medicenna Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MDNA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MDNA vs. The Competition

Export
MetricMedicenna TherapeuticsBiotechnology IndustryMedical SectorTSE Exchange
Market CapC$36.29MC$455.88MC$6.26BC$12.11B
Dividend YieldN/A3.87%2.69%6.21%
P/E Ratio-2.903.1622.3737.78
Price / SalesN/A6,509.16547.5711.32
Price / Cash1.1513.1342.3182.29
Price / Book5.8484.749.794.59
Net Income-C$25.98M-C$96.07MC$3.56BC$299.09M
7 Day Performance2.35%-0.05%-1.27%0.66%
1 Month Performance-28.69%0.69%3.58%1.55%
1 Year Performance-53.72%73.12%27.13%51.51%

Medicenna Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MDNA
Medicenna Therapeutics
N/AC$0.44
+3.6%		N/A-56.3%C$36.29MN/AN/A20
APM
Andean Precious Metals
N/AC$1.29
+7.5%		N/A+0.0%C$135.47MC$154.78M2.5530
GXE
Gear Energy
N/AN/AN/AN/AC$126.52MC$134.93M10.391,310
CGC
Canadian Gold
N/AC$0.60
-6.3%		N/A+126.4%C$126.35MN/AN/A3,150
WMD
WeedMD
N/AC$0.28
-1.8%		N/A+0.0%C$67.82MC$27.53MN/A628

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:MDNA) was last updated on 6/3/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel
SpaceX IPO hides a much bigger story
The SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...
Weiss Ratings | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
Elon’s AI supercomputer just went live. Here’s my #1 stock.
Is Elon about to trigger another 315X opportunity? Elon gave Tesla investors the chance to make more than 3...
InvestorPlace | Sponsoredtc pixel